Role of adjunctive medical therapy in the fetoscopic surgical treatment of twin-twin transfusion syndrome

Michael V. Zaretsky, Stig Somme, Timothy M. Crombleholme

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The underlying etiology of twin-twin transfusion syndrome (TTTS) is unknown, but our growing understanding of the cardiovascular features of TTTS suggests this may be a disease that could respond to transplacental medical therapy. Adjunctive medical therapy in TTTS with the calcium channel blocker nifedipine has been shown to improve recipient survival while having no effect on the donor. There is no significant difference in recipient survival from postoperative day 5 to birth suggesting that the survival benefit is confined to the effects of nifedipine in the perioperative period. Also, there is no significant effect of nifedipine on gestational age at delivery suggesting the survival benefit was unrelated to the tocolytic effects of nifedipine and more likely a result of hemodynamic effects in the recipient twins' cardiovascular system during the perioperative period. TTTS remains poorly understood but there appears to be good evidence suggesting twin-twin hypertensive cardiomyopathy is a large component of the pathophysiology in recipient twins. The initial findings of nifedipine's effectiveness as a targeted medical therapy to address TTTS cardiomyopathy and improve survival of recipient twins opens the door for further research for adjunctive medical therapies in TTTS.

Original languageEnglish (US)
JournalAmerican Journal of Perinatology
Volume31
Issue numberSUPPL. 1
DOIs
StatePublished - 2014

Fingerprint

Fetofetal Transfusion
Nifedipine
Perioperative Period
Cardiomyopathies
Therapeutics
Tocolytic Agents
Calcium Channel Blockers
Cardiovascular System
Gestational Age
Biomedical Research
Hemodynamics
Parturition

Keywords

  • fetoscopic laser surgery
  • nifedipine
  • twin-twin transfusion syndrome
  • twin-twin transfusion syndrome cardiomyopathy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Role of adjunctive medical therapy in the fetoscopic surgical treatment of twin-twin transfusion syndrome. / Zaretsky, Michael V.; Somme, Stig; Crombleholme, Timothy M.

In: American Journal of Perinatology, Vol. 31, No. SUPPL. 1, 2014.

Research output: Contribution to journalArticle

Zaretsky, Michael V. ; Somme, Stig ; Crombleholme, Timothy M. / Role of adjunctive medical therapy in the fetoscopic surgical treatment of twin-twin transfusion syndrome. In: American Journal of Perinatology. 2014 ; Vol. 31, No. SUPPL. 1.
@article{2d30730a50d24a2cb76af84fb646ae80,
title = "Role of adjunctive medical therapy in the fetoscopic surgical treatment of twin-twin transfusion syndrome",
abstract = "The underlying etiology of twin-twin transfusion syndrome (TTTS) is unknown, but our growing understanding of the cardiovascular features of TTTS suggests this may be a disease that could respond to transplacental medical therapy. Adjunctive medical therapy in TTTS with the calcium channel blocker nifedipine has been shown to improve recipient survival while having no effect on the donor. There is no significant difference in recipient survival from postoperative day 5 to birth suggesting that the survival benefit is confined to the effects of nifedipine in the perioperative period. Also, there is no significant effect of nifedipine on gestational age at delivery suggesting the survival benefit was unrelated to the tocolytic effects of nifedipine and more likely a result of hemodynamic effects in the recipient twins' cardiovascular system during the perioperative period. TTTS remains poorly understood but there appears to be good evidence suggesting twin-twin hypertensive cardiomyopathy is a large component of the pathophysiology in recipient twins. The initial findings of nifedipine's effectiveness as a targeted medical therapy to address TTTS cardiomyopathy and improve survival of recipient twins opens the door for further research for adjunctive medical therapies in TTTS.",
keywords = "fetoscopic laser surgery, nifedipine, twin-twin transfusion syndrome, twin-twin transfusion syndrome cardiomyopathy",
author = "Zaretsky, {Michael V.} and Stig Somme and Crombleholme, {Timothy M.}",
year = "2014",
doi = "10.1055/s-0034-1384641",
language = "English (US)",
volume = "31",
journal = "American Journal of Perinatology",
issn = "0735-1631",
publisher = "Thieme Medical Publishers",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Role of adjunctive medical therapy in the fetoscopic surgical treatment of twin-twin transfusion syndrome

AU - Zaretsky, Michael V.

AU - Somme, Stig

AU - Crombleholme, Timothy M.

PY - 2014

Y1 - 2014

N2 - The underlying etiology of twin-twin transfusion syndrome (TTTS) is unknown, but our growing understanding of the cardiovascular features of TTTS suggests this may be a disease that could respond to transplacental medical therapy. Adjunctive medical therapy in TTTS with the calcium channel blocker nifedipine has been shown to improve recipient survival while having no effect on the donor. There is no significant difference in recipient survival from postoperative day 5 to birth suggesting that the survival benefit is confined to the effects of nifedipine in the perioperative period. Also, there is no significant effect of nifedipine on gestational age at delivery suggesting the survival benefit was unrelated to the tocolytic effects of nifedipine and more likely a result of hemodynamic effects in the recipient twins' cardiovascular system during the perioperative period. TTTS remains poorly understood but there appears to be good evidence suggesting twin-twin hypertensive cardiomyopathy is a large component of the pathophysiology in recipient twins. The initial findings of nifedipine's effectiveness as a targeted medical therapy to address TTTS cardiomyopathy and improve survival of recipient twins opens the door for further research for adjunctive medical therapies in TTTS.

AB - The underlying etiology of twin-twin transfusion syndrome (TTTS) is unknown, but our growing understanding of the cardiovascular features of TTTS suggests this may be a disease that could respond to transplacental medical therapy. Adjunctive medical therapy in TTTS with the calcium channel blocker nifedipine has been shown to improve recipient survival while having no effect on the donor. There is no significant difference in recipient survival from postoperative day 5 to birth suggesting that the survival benefit is confined to the effects of nifedipine in the perioperative period. Also, there is no significant effect of nifedipine on gestational age at delivery suggesting the survival benefit was unrelated to the tocolytic effects of nifedipine and more likely a result of hemodynamic effects in the recipient twins' cardiovascular system during the perioperative period. TTTS remains poorly understood but there appears to be good evidence suggesting twin-twin hypertensive cardiomyopathy is a large component of the pathophysiology in recipient twins. The initial findings of nifedipine's effectiveness as a targeted medical therapy to address TTTS cardiomyopathy and improve survival of recipient twins opens the door for further research for adjunctive medical therapies in TTTS.

KW - fetoscopic laser surgery

KW - nifedipine

KW - twin-twin transfusion syndrome

KW - twin-twin transfusion syndrome cardiomyopathy

UR - http://www.scopus.com/inward/record.url?scp=84906790334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906790334&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1384641

DO - 10.1055/s-0034-1384641

M3 - Article

C2 - 25077476

AN - SCOPUS:84906790334

VL - 31

JO - American Journal of Perinatology

JF - American Journal of Perinatology

SN - 0735-1631

IS - SUPPL. 1

ER -